Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle

British Journal of Cancer

Volumn 98, Issue 2, 2008, Pages 356-362

  Kumano, M ^a   Miyake, H ^a   Kurahashi, T ^a   Yamanaka, K ^a   Fujisawa, M ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasion; Prostate cancer; Seminal vesicle; Transforming growth factor 1; Urokinase type plasminogen activator

Indexed keywords

CYTOKINE; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CULTURE; CELL GROWTH; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; MICROENVIRONMENT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SCID MOUSE; SEMINAL VESICLE; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; EXTRACELLULAR FLUID; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; PHENOTYPE; PROSTATIC NEOPLASMS; SEMINAL VESICLES; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 38549119090     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604169     Document Type: Article

References (24)

1. Alencar H, King R, Funovics M, Stout C, Weissleder R, Mahmood U (2005) A novel mouse model for segmental orthotopic colon cancer. Int J Cancer 117: 335-339
2. Barton J, Blackledge G, Wakeling A (2001) Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58: 114-122
3. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC (2005) Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 7: 241-252
4. Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV (2004) Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 63: 333-336
5. Choong PF, Nadesapillai AP (2003) Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415: S46-S58
6. Desruisseau S, Ghazarossian-Ragni E, Chinot O, Martin PM (1996) Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Int J Cancer 66: 796-801
7. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, Bologna M (2000) Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85: 407-415
8. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulated invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16: 513-528
9. Fidler IJ (1990) Critical factors in the biology human cancer metastasis: twenty-eighth G. G. A. Clowes memorial award lecture. Cancer Res 50: 6130-6138
10. Gohji K, Nakajima M, Boyd D, Dinney CP, Bucana CD, Kitazana S, Kamidono S, Fidler IJ (1997) Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol 151: 1655-1661
11. Masterson TA, Pettus JA, Middleton RG, Stephenson RA (2005) Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. Urology 66: 152-155
12. Matalliotakis I, Sifakis S, Goumemou A, Fragouli Y, Neonaki M, Matalliotakis G, Koumantakis E (1998) Cytokine levels in seminal plasma. Clin Exp Obstet Gynecol 25: 58-60
13. Miyake H, Hara I, Gohji K, Yamanaka K, Hara S, Arakawa S, Nakajima M, Kamidono S (1999a) Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin Cancer Res 5: 2824-2829
14. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999b) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39: 123-129
15. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-36540
16. Robertson SA (2005) Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res 322: 43-52
17. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A (2001) Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 98: 2658-2663
18. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD (1997) A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 57: 1584-1589
19. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25: 349-355
20. Sofer M, Savoie M, Kim SS, Civantos F, Soloway MS (2003) Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 169: 153-156
21. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR (2002) Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62: 6021-6025
22. Unlu A, Leake RE (2003) Transforming growth factor β1 stimulates urokinase plasminogen activator system on prostate cancer cells. Int J Biol Markers 18: 147-151
23. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brunner N, Hoyer-Hansen G, Andreasen P, Dano K, Nielsen BS (2005) Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113: 870-880
24. Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H (2005) Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 4: 187-195